The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPacific Biosciences of California (PacBio) shares saw an uptick following the unveiling of a new FFPE workflow developed in collaboration with Covaris. This innovation is specifically designed to enhance the accuracy of HiFi sequencing, unlocking critical genomic insights from archived tumor samples. By addressing the technical hurdles inherent in sequencing formalin-fixed paraffin-embedded tissues, the partnership expands the utility of PacBio’s platforms in oncology research. This technological advancement is expected to broaden the company's addressable market within the clinical and diagnostic sectors. Investor sentiment remains positive as the move strengthens PacBio's competitive edge in the high-growth genomics industry. The workflow represents a strategic step forward in improving the precision of cancer sequencing and personalized medicine.